Becalming Type 17 Inflammation in Ulcerative Colitis

Hannah H Chen; Alison Simmons

doi:10.1016/j.immuni.2019.03.019

Becalming Type 17 Inflammation in Ulcerative Colitis

Immunity. 2019 Apr 16;50(4):1029-1031. doi: 10.1016/j.immuni.2019.03.019.

Authors

Hannah H Chen¹, Alison Simmons²

Affiliations

¹ MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK; Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.
² MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK; Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK. Electronic address: alison.simmons@imm.ox.ac.uk.

PMID: 30995495
DOI: 10.1016/j.immuni.2019.03.019

Abstract

Genome-wide association studies in ulcerative colitis point to a role for FcγRIIA, a receptor for IgG. Castro-Dopico et al. (2019) find a profound induction of anti-commensal IgG in the colonic mucosa of UC patients and outline a pathway whereby FcγR activation by IgG triggers IL-1β production, type 17 immunity, and the exacerbation of inflammation.

Publication types

Comment

MeSH terms

Colitis*
Colitis, Ulcerative*
Colon
Genome-Wide Association Study
Humans
Immunoglobulin G
Inflammation
Intestinal Mucosa

Substances

Immunoglobulin G

Abstract

Publication types

MeSH terms

Substances

Grants and funding